1.55
전일 마감가:
$1.57
열려 있는:
$1.52
하루 거래량:
15,003
Relative Volume:
0.99
시가총액:
$54.83M
수익:
$1.88M
순이익/손실:
$-15.57M
주가수익비율:
-3.875
EPS:
-0.4
순현금흐름:
$-50.09M
1주 성능:
+13.97%
1개월 성능:
+7.64%
6개월 성능:
-30.11%
1년 성능:
-30.18%
Beyondspring Inc Stock (BYSI) Company Profile
명칭
Beyondspring Inc
전화
646-528-4184
주소
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
BYSI을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BYSI
Beyondspring Inc
|
1.55 | 54.83M | 1.88M | -15.57M | -50.09M | -0.40 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-12-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
2021-12-02 | 다운그레이드 | Jefferies | Buy → Hold |
2021-12-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2021-12-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2021-09-09 | 개시 | Robert W. Baird | Outperform |
2021-08-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2021-04-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2021-01-11 | 개시 | BofA Securities | Buy |
2020-12-29 | 개시 | Evercore ISI | Outperform |
2020-02-07 | 개시 | Jefferies | Buy |
2020-01-10 | 개시 | Nomura | Buy |
2019-12-03 | 개시 | William Blair | Outperform |
2019-07-10 | 재확인 | H.C. Wainwright | Buy |
2019-04-30 | 다운그레이드 | Maxim Group | Buy → Hold |
2018-10-25 | 재확인 | Maxim Group | Buy |
모두보기
Beyondspring Inc 주식(BYSI)의 최신 뉴스
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring (NASDAQ:BYSI) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
BeyondSpring stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.34 amid market challenges - Investing.com India
BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat
BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com
BeyondSpring Inc. (BYSI) reports earnings - Quartz
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times
BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewswire
Just Released: BeyondSpring's Complete 2024 Financial Performance and Cancer Pipeline Updates - Stock Titan
Global Febrile Neutropenia Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, And - EIN News
In-Depth Analysis Of The Global Febrile Neutropenia Market Advancements Highlighted by Key Drivers, Trends,... - WhaTech
BeyondSpring's PlinabulinA Pipeline In Itself? - RTTNews
Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
BeyondSpring, Inc. to Host Earnings Call - ACCESS Newswire
Pliant Therapeutics stock tumbles amid IPF trial cancellation - Clinical Trials Arena
BeyondSpring finalizes significant asset sale By Investing.com - Investing.com South Africa
BeyondSpring finalizes significant asset sale - Investing.com India
BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.6%Time to Buy? - MarketBeat
Cancer Vaccines Market on Track for Major Expansion in - One News Page
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights
BeyondSpring Inc. Enters into Preferred Share Purchase Agreement with SEED Therapeutics Inc. - Defense World
BeyondSpring sells SEED Therapeutics shares for $35.4M - MSN
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - The Manila Times
BeyondSpring sells SEED Therapeutics shares for $35.4M By Investing.com - Investing.com UK
BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire
SEED Receives FDA Rare Pediatric Disease and Orphan Drug - GlobeNewswire
BeyondSpring Cashes In $35M Stake as Cancer Drug Shows 89% Disease Control Rate - StockTitan
BeyondSpring (NASDAQ:BYSI) Shares Down 1.4%Here's Why - MarketBeat
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve
BeyondSpring Inc. Announces Change in Domestic Filing Status and Disclosure Channels to Disseminate Information - Defense World
Beyondspring Inc (BYSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):